ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer

2017323 citationsJournal Articlebronze Open Access

Authors

Filippo Pietrantonio · Fondazione IRCCS Istituto Nazionale dei Tumori

Federica Di Nicolantonio · Istituti di Ricovero e Cura a Carattere Scientifico

Alexa B. Schrock · Foundation Medicine (United States)

Jeeyun Lee · Sungkyunkwan University

Sabine Tejpar

Andrea Sartore‐Bianchi · Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda

Jaclyn F. Hechtman ·

Abstract

ALK, ROS1, and NTRK rearrangements define a new rare subtype of mCRC with extremely poor prognosis. Primary tumor site, MSI-high, and RAS and BRAF wild-type status may help to identify patients bearing these alterations. While sensitivity to available treatments is limited, targeted strategies inhibiting ALK, ROS, and TrkA-B-C provided encouraging results.

Topics & Keywords

Colorectal Cancer Treatments and Studies Genetic factors in colorectal cancer Lung Cancer Treatments and Mutations

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JNCI Journal of the National Cancer Institute

Volume 109, Issue 12

DOI: 10.1093/jnci/djx089

Field-Weighted Citation Impact: 16.82